Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University, School of Medicine, New Haven, CT, USA.
Division of Health Care Sciences, Center for Clinical Research and Management Education, Dresden International University, Dresden, Germany.
Reprod Sci. 2019 Jul;26(7):939-953. doi: 10.1177/1933719118799203. Epub 2018 Oct 1.
A systematic review and meta-analysis was conducted to investigate whether gonadotropin-releasing hormone analogs (GnRHa) have a protective role in women treated with alkylating agents.
Major databases (PubMED, EMBASE, Cochrane Central Register of Controlled Trials), systematic snowballing, and trial registries were screened from the inception dates until September 2017.
Comparative studies involving reproductive-aged women undergoing chemotherapy with or without coadministration of GnRHa were included. Spontaneous menstrual resumption was assessed as a main outcome. Statistical analyses were performed with STATA 14.2 statistical software. Effect estimates were presented as risk ratios (RR) with 95% confidence intervals (CIs).
The literature search yielded 25 436 citations and 84 papers were assessed in full text. Eighteen studies (11 randomized controlled trials [RCTs] and 7 cohort studies) published between 1987 and 2015 were included in the analysis, revealing a significant protective effect of GnRHa (n = 1043; RR:1.38; 95% CI: 1.18-1.63) although with high heterogeneity (I = 83.3%). Subgroup analyses revealed a significant benefit of GnRHa cotreatment both in RCTs and in cohort studies. Statistical significance was found in all subgroups by the underlying disease, that is, hematological malignancies, autoimmune diseases, and breast cancer. Sensitivity analyses in GnRH agonist-treated patients, in patients younger than 40 years old, and in patients without supradiaphragmatic radiotherapy also revealed a significant benefit of GnRHa cotreatment.
Our results indicate that concurrent GnRHa administration is an effective method to decrease gonadotoxicity of alkylating agents. The presence of low-quality evidence favoring gonadoprotective effect requires a strong recommendation for offering GnRHa coadministration to young women who are to undergo gonadotoxic chemotherapy.
The present systematic review and meta-analysis shows a significant gonadoprotective effect of gonadotropin-releasing hormone analogs in women treated with alkylating agents.
系统回顾和荟萃分析旨在研究促性腺激素释放激素类似物(GnRHa)是否对接受烷化剂治疗的女性具有保护作用。
主要数据库(PubMED、EMBASE、Cochrane 对照试验中心注册库)、系统滚雪球法和试验注册库均从成立日期开始筛选,直至 2017 年 9 月。
纳入比较研究,涉及接受化疗的育龄期女性,包括或不包括 GnRHa 联合治疗。自发月经恢复作为主要结局进行评估。统计分析采用 STATA 14.2 统计软件进行。效应估计值以风险比(RR)和 95%置信区间(CI)表示。
文献检索得到 25436 条引文,84 篇全文进行了评估。纳入 1987 年至 2015 年期间发表的 18 项研究(11 项随机对照试验[RCT]和 7 项队列研究),分析结果显示 GnRHa 具有显著的保护作用(n=1043;RR:1.38;95%CI:1.18-1.63),尽管存在高度异质性(I=83.3%)。亚组分析显示 GnRHa 联合治疗在 RCT 和队列研究中均有显著获益。根据潜在疾病(即血液恶性肿瘤、自身免疫性疾病和乳腺癌)进行亚组分析时,结果具有统计学意义。在 GnRH 激动剂治疗患者、年龄小于 40 岁患者和无膈上放疗患者的敏感性分析中,GnRHa 联合治疗也显示出显著获益。
我们的研究结果表明,同时使用 GnRHa 是降低烷化剂性腺毒性的有效方法。虽然存在低质量证据支持性腺保护作用,但强烈建议对接受性腺毒性化疗的年轻女性提供 GnRHa 联合治疗。
本系统回顾和荟萃分析表明,促性腺激素释放激素类似物对接受烷化剂治疗的女性具有显著的性腺保护作用。